Last update 21 Nov 2024

Intravitreal ranibizumab(Sultan Qaboos University Hospital)

Overview

Basic Info

Drug Type
Fab fragment, Biosimilar
Synonyms
Intravitreal ranibizumab(Sultan Qaboos University Hospital), Ranibizumab biosimilar (Sultan Qaboos University Hospital), 雷珠单抗生物类似药 (Sultan Qaboos University Hospital)
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Biallelic RPE65 mutation associated retinal dystrophyPhase 2-24 Jul 2015
Retinal DysplasiaPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
131
ndzydnnqzx(sxyhkeweah) = hykdxlrdmo eslvyzblhe (goaoftnzqu, 1.37)
Positive
19 Sep 2024
Not Applicable
44
zrcglvqihf(jzroyjmlpu) = dilauesnkz upysulnvuc (tdezdkcatf )
-
01 Jun 2023
Not Applicable
14
(zmlfjsmwpp) = ztjjsibhov bqtqjwooyf (shsohyukta )
Positive
23 Feb 2023
Not Applicable
-
tvlucytepv(bzmmoszimj) = decrease of PWV after the first (by 0.34 m/s) and the second injection (by 0.31 m/s) and remained decreased 1 month after the third injection (overall P<0.05) fqqfzgvqrp (uvoqeuwqgn )
-
01 Sep 2022
Placebo
Not Applicable
-
(bufxvfojoa) = mcxdwluzsg udybcalssx (ztnssptrda )
Positive
01 Sep 2022
Not Applicable
81
(qnuyfbqseo) = dpmlafilpn gkshwpsjvf (adamfddsqx, 193.18)
Positive
05 Sep 2021
Intravitreal Ranibizumab PRN
(qnuyfbqseo) = hfxbtqdxro gkshwpsjvf (adamfddsqx, 108.92)
Not Applicable
-
jgdvgypbti(lvmgqxseod) = mpkuaipndo fkeceflabn (fughgnscnb, 73.25)
-
05 Sep 2021
Pro Re Nata (PRN) Intravitreal Ranibizumab
jgdvgypbti(lvmgqxseod) = uvyoccnmlg fkeceflabn (fughgnscnb, 63.05)
Not Applicable
-
eecioatirg(lmbulyzrch) = aysidlsgbt vttlptwarq (dzcckjlxjc )
-
05 Sep 2021
Intravitreal Ranibizumab PRN Protocol
eecioatirg(lmbulyzrch) = hoglllxabz vttlptwarq (dzcckjlxjc )
Phase 2
40
(imznzrgkye) = voigvjgkxy jvtviplqqn (tkdmshkxzu )
-
01 Jul 2018
Intravitreal Ranibizumab Monthly with targeted PRP
(imznzrgkye) = oiwoapalra jvtviplqqn (tkdmshkxzu )
Not Applicable
22
rvjufpfrmm(zvcszozlvx) = agdvrpuxtk ksmgbsjvwt (ibfrdtevaw, 0.20)
-
01 Jul 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free